Cargando…
Therapeutic effects of TP5, a Cdk5/p25 inhibitor, in in vitro and in vivo models of Parkinson’s disease
Parkinson’s Disease (PD) is a chronic progressive neurodegenerative disease. Current treatments for PD are symptomatic and only increase striatal dopamine levels. Proactive neuroprotective approaches that slow the progression of PD and maintain appropriate dopamine neuron populations are needed to t...
Autores principales: | Tran, Judith, Taylor, Shane K.B., Gupta, Anika, Amin, Niranjana, Pant, Harish, Gupta, Bhagwati P., Mishra, Ram K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559888/ https://www.ncbi.nlm.nih.gov/pubmed/36246507 http://dx.doi.org/10.1016/j.crneur.2021.100006 |
Ejemplares similares
-
Peptide TFP5/TP5 derived from Cdk5 activator P35 provides neuroprotection in the MPTP model of Parkinson’s disease
por: Binukumar, BK., et al.
Publicado: (2015) -
TP5: A Novel Therapeutic Approach Targeting Aberrant and Hyperactive CDK5/p25 for the Treatment of Colorectal Carcinoma
por: Amin, Niranjana, et al.
Publicado: (2023) -
TP5, a Peptide Inhibitor of Aberrant and Hyperactive CDK5/p25: A Novel Therapeutic Approach against Glioblastoma
por: Tabouret, Emeline, et al.
Publicado: (2020) -
Cdk5 Inhibitory Peptide (CIP) Inhibits Cdk5/p25 Activity Induced by High Glucose in Pancreatic Beta Cells and Recovers Insulin Secretion from p25 Damage
por: Zheng, Ya-Li, et al.
Publicado: (2013) -
TFP5/TP5 peptide provides neuroprotection in the MPTP model of Parkinson's disease
por: Binukumar, BK, et al.
Publicado: (2016)